Funke Jerod
Known title: EVP-Chief HR OfficerCIK: 0001998115
Funke Jerod's purchase track record
Funke Jerod has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/20/2024 | INFU | $6K | -1.8% | +38.5% | +11.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INFU | ▲ Buy | Grant | 14,570 | $0 | 5/17/2026 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 6,462 | $57K | 5/17/2026 | View on chart |
| INFU | ▲ Buy | Option Exercise | 5,183 | $0 | 5/16/2026 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 2,299 | $20K | 5/16/2026 | View on chart |
| INFU | ▲ Buy | Option Exercise | 12,500 | $0 | 10/9/2025 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 3,669 | $35K | 10/9/2025 | View on chart |
| INFU | ▲ Buy | Option Exercise | 12,500 | $0 | 10/9/2024 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 3,669 | $25K | 10/9/2024 | View on chart |
| INFU | ▲ Buy | Open Market | 1,000 | $6K | 5/20/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
INFU Shares Business Overview, Emphasizes Patient-First Strategy
INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.
INFU Shares Business Overview, Emphasizes Patient-First Strategy. INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.